So far, 30 healthy adult humans have been dosed with NMRA-266, a positive allosteric modulator of the M4 muscarinic receptor, as part of the single and multiple-ascending-dose phase 1 study. None of these patients have shown any evidence of convulsions, Neumora stressed.
1 Like
*Reports of larger ears and hopping have been noted though!
2 Likes
Neumora is not the only company developing a drug for the disease — Karuna and Cerevel are developing similar treatments for schizophrenia.
Karuna read out Phase 3 data last year for KarXT, an M1/M4-preferring muscarinic agonist, and is awaiting a September FDA decision. However, it did have to delay readouts from three studies, Karuna announced in February. Bristol Myers Squibb completed an acquisition of Karuna in March of this year.
Cerevel is also waiting on Phase 2 data for its drug emraclidine, its lead schizophrenia and Alzheimer’s disease psychosis drug candidate that also modulates the muscarinic 4 receptor.
1 Like